Clinical Trial Update: AGN-CognI.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and pharmacokinetics (acute dose, dose-response) of AGN-CognI.Q in prostate cancer patients. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• AGN-CognI.Q

Snippet

Sponsor: Milton S. Hershey Medical Center | Conditions: Prostate Cancer | Phase 1 | Status: COMPLETED